Enlivex Ltd.’s SEC filings document its status as an Israeli foreign private issuer with ordinary shares listed under ENLV, its clinical-stage Allocetra™ program, and its prediction markets treasury strategy centered on the RAIN token and Rain protocol.
Recent Form 6-K reports furnish current disclosures on regulatory clearances for Allocetra™ in age-related knee osteoarthritis, annual financial results, tokenized representations of the company’s ordinary shares, Rain protocol ecosystem updates, senior secured convertible debt, and the completed corporate name change from Enlivex Therapeutics Ltd. to Enlivex Ltd. The filings also reference registration statements and governance records tied to shareholder approvals and capital structure.
Enlivex Therapeutics Ltd. (ENLV) reported that it held its 2025 Annual General Meeting of Shareholders on November 17, 2025. Shareholders voted on proposals described in the earlier notice and proxy statement, and each proposal was approved by the required majority. The company also stated that this report is incorporated by reference into its existing registration statements on Forms S-8 and F-3, which helps keep those filings updated with its latest corporate actions.
Enlivex Therapeutics Ltd. reported that its 2025 Annual General Meeting of Shareholders was convened but adjourned due to a lack of quorum. The meeting will reconvene on November 17, 2025 at 7:00 p.m. Israel time at the company’s offices in Nes Ziona, Israel.
Voting deadlines were extended: mailed proxies are due by November 14, 2025 at 7:00 p.m. Israel time, and telephone or internet voting is open until November 13, 2025 at 11:59 p.m. Eastern time. Shareholders holding through the Tel Aviv Stock Exchange may vote in person with an Ownership Certificate, by proxy with an Ownership Certificate delivered by November 13, 2025 at 7:00 p.m. Israel time, or electronically via the Israel Securities Authority system until 1:00 p.m. Israel time on November 17, 2025.
Enlivex Therapeutics Ltd. filed a Form 6-K to report its Annual General Meeting of Shareholders is scheduled for November 10, 2025 at 7:00 p.m. Israel time at the company's offices, 14 Einstein Street, Nes Ziona, Israel. The report states that the meeting notice, proxy statement and a form of proxy card are attached as Exhibit 99.1 and Exhibit 99.2 and are incorporated by reference into the report. The filing is signed by CEO Oren Hershkovitz.
Enlivex Therapeutics Ltd. furnished a report describing a new communication to shareholders. The company’s Chief Executive Officer sent a letter outlining Enlivex’s strategic roadmap following positive Phase IIa Allocetra™ results. This shareholder letter, dated September 11, 2025, is attached as Exhibit 99.1 to the report.
Enlivex Therapeutics Ltd. reported that it has received an Israeli patent covering methods of using its Allocetra™ therapy to treat osteoarthritis. The patent extends Enlivex’s intellectual property protection in Israel through at least 2040, strengthening the company’s legal protection around this specific therapeutic use.
Enlivex Therapeutics Ltd. filed a Form 6-K as a foreign private issuer, furnishing its unaudited condensed consolidated financial statements for the three and six month periods ended June 30, 2025 and 2024. The filing also includes an Operating and Financial Review and Prospects for the same periods, provided as Exhibits 99.1 and 99.2. These materials are incorporated by reference into Enlivex’s existing registration statements on Forms S-8 and F-3, allowing those registration statements to use the latest interim financial and operating information.
Enlivex Therapeutics Ltd. filed a Form 6-K stating that on August 18, 2025 it posted an updated investor presentation on its website. The company furnished this presentation as Exhibit 99.1 to the report, making it available to the market through the SEC system.
The information on slides 10 through 24 of the presentation is explicitly incorporated by reference into Enlivex’s existing registration statements on Forms S-8 and F-3, including an F-3MEF. This means those specific slides now form part of the legal disclosure package that supports Enlivex’s registered securities offerings in the United States.
Enlivex Therapeutics Ltd. filed a Form 6-K to furnish a press release announcing three-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled trial of Allocetra™ in patients with moderate-to-severe knee osteoarthritis. The press release, dated August 18, 2025, is attached as Exhibit 99.1. The information in the two bullets immediately under the heading “ENX-CL-05-001 Trial: 3-months topline data” in that press release is also incorporated by reference into Enlivex’s existing registration statements on Forms S-8, F-3 and F-3MEF.
Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A reporting shared beneficial ownership of 1,178,389 ordinary shares of Enlivex Therapeutics Ltd. (CUSIP 05280R100), representing 4.99% of the class. Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., states it exercises voting and investment power over the shares held by the Master Fund; Mr. Boyd, as managing member, is similarly reported. The filing affirms the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Enlivex Therapeutics Ltd. filed a Form 6-K noting it will host a webinar on August 18, 2025, at 8:00 Eastern Time. During the event, the company plans to present and discuss 3‑month topline results from the Phase IIa stage of its Phase I/IIa ENX-CL-05-001 clinical trial. This double-blind, randomized, placebo-controlled, multi-center study is evaluating its Allocetra™ therapy in patients with moderate-to-severe knee osteoarthritis. The related press release, dated August 14, 2025, is furnished as Exhibit 99.1.